We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+8.13%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$988M
AUM Growth
-$31.3M
Cap. Flow
-$56.5M
Cap. Flow %
-5.72%
Top 10 Hldgs %
45.25%
Holding
164
New
47
Increased
25
Reduced
25
Closed
38

Top Buys

Rank Stock Value
1
OTIC
Otonomy, Inc.
OTIC
+$16.6M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$11.4M
3
ARWR icon
Arrowhead Research
ARWR
+$11.3M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.4M
5
EPZM
Epizyme, Inc
EPZM
+$7.5M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$37M
2
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$24.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.9M
4
SHPG
Shire pic
SHPG
+$21.2M
5
INSM icon
Insmed
INSM
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 79.83%
2 Financials 0.18%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELOS
76
DELISTED
Syneron Medical Ltd
ELOS
$1.5M 0.15%
150,000
+35,000
+30% +$356K
CLVS
77
DELISTED
Clovis Oncology, Inc.
CLVS
$1.4M 0.14%
30,917
+20,000
+183% +$835K
DRRX
78
DELISTED
DURECT Corp
DRRX
$1.33M 0.13%
90,706
– –
PARN
79
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$1.21M 0.12%
+210,000
New +$1.26M
MNKD icon
80
PUT
MannKind Corp
MNKD
$1.19B
$1.18M 0.12%
+40,000
New +$1.58M
SNN icon
81
Smith & Nephew
SNN
$13.7B
$1.09M 0.11%
32,408
-25,000
-44% -$872K
ANTH
82
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$919K 0.09%
59,807
– –
NGNE icon
83
Neurogene
NGNE
$672M
$866K 0.09%
6,500
– –
PRPO icon
84
Precipio
PRPO
$39.1M
$692K 0.07%
20
– –
GLMD icon
85
Galmed Pharmaceuticals
GLMD
$4.62M
$645K 0.07%
417
– –
VXRT
86
DELISTED
Vaxart
VXRT
$626K 0.06%
23,036
– –
CASC
87
DELISTED
Cascadian Therapeutics, Inc.
CASC
$624K 0.06%
54,167
+5,370
+11% +$82K
ABMD
88
DELISTED
Abiomed Inc
ABMD
$621K 0.06%
+25,000
New +$633K
MTEM
89
DELISTED
Molecular Templates, Inc.
MTEM
$578K 0.06%
+970
New +$671K
AKAO
90
DELISTED
Achaogen Inc
AKAO
$538K 0.05%
60,000
– –
GNMX
91
DELISTED
Aevi Genomic Medicine Inc
GNMX
$286K 0.03%
55,073
– –
OXGN
92
DELISTED
OXIGENE INC COM
OXGN
$266K 0.03%
123,518
-255,682
-67% -$594K
NXTM
93
DELISTED
NxStage Medical Inc.
NXTM
$263K 0.03%
+20,000
New +$269K
PTX
94
CALL
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$192K 0.02%
+2,500
New +$197K
ICLR icon
95
Icon
ICLR
$13.7B
$140K 0.01%
2,440
– –
CBPO
96
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$130K 0.01%
2,400
– –
AMN icon
97
AMN Healthcare
AMN
$1.35B
$123K 0.01%
+7,855
New +$112K
MODV
98
DELISTED
ModivCare
MODV
$122K 0.01%
+2,532
New +$108K
ENTA icon
99
Enanta Pharmaceuticals
ENTA
$362M
$120K 0.01%
+3,040
New +$121K
MGLN
100
DELISTED
Magellan Health Services, Inc.
MGLN
$120K 0.01%
2,189
+547
+33% +$31.4K
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2014 Portfolio in Review

As of Q3 2014, Perceptive Advisors held 164 positions worth $988M, down 3.1% from $1.02B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $56.5M in Q3 2014, closing 38 positions and reducing 25 holdings. Its most notable exit was QUESTCOR PHARMA INC, an estimated $37M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Perceptive Advisors opened a new position in Otonomy, Inc. worth $20.1M.

  • Perceptive Advisors's largest Q3 2014 buy was Otonomy, Inc.: 837,400 shares worth $20.1M.
  • Perceptive Advisors added most to Arrowhead Research in Q3 2014, an estimated $11.3M increase.
  • Perceptive Advisors's biggest Q3 2014 reduction was Taro Pharmaceutical Industries Ltd., cutting an estimated $24.1M.
  • Perceptive Advisors fully exited QUESTCOR PHARMA INC in Q3 2014, selling an estimated $37M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $988M portfolio in Q3 2014.
  • Perceptive Advisors opened 47 new positions and closed 38 in Q3 2014.
  • Perceptive Advisors's portfolio value fell 3.1% quarter-over-quarter to $988M.

Based on Perceptive Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.